Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers
- PMID: 2023879
- DOI: 10.1023/a:1015864709082
Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers
Abstract
The pharmacokinetics and pharmacodynamics of methylprednisolone were investigated after intravenous administration of methylprednisolone phosphate to healthy subjects at seven different doses (16 to 1000 mg). Forty different pharmacodynamic parameters were followed for 1 week. The pharmacodynamic data were analyzed as a function of time as well as cumulative effects in form of the areas under the effect-time curves. Statistically significant dose-dependent effects of methylprednisolone were observed for 15 pharmacodynamic parameters. Highly significant (P less than or equal to 0.0001) effects were increases in glucose levels, number of white blood cells, and segmented granulocytes as well as a decrease in the number of lymphocytes. For these pharmacodynamic effects an integrated pharmacokinetic/pharmacodynamic model was derived that translates the methylprednisolone plasma concentration-time profiles into effect-time profiles. This model allows prediction of pharmacodynamic effects for any single dose in the range studied at any time point.
Similar articles
-
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.Pharm Res. 1995 Jul;12(7):1096-100. doi: 10.1023/a:1016287104656. Pharm Res. 1995. PMID: 7494809 Clinical Trial.
-
Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids.J Clin Pharmacol. 1993 Feb;33(2):115-23. doi: 10.1002/j.1552-4604.1993.tb03930.x. J Clin Pharmacol. 1993. PMID: 8440759 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of methylprednisolone when administered at 8 am versus 4 pm.Clin Pharmacol Ther. 1992 Jun;51(6):677-88. doi: 10.1038/clpt.1992.80. Clin Pharmacol Ther. 1992. PMID: 1535301 Free PMC article. Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
[Problems of equivalency points during therapy with glucocorticoids. A comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone].Dtsch Med Wochenschr. 1994 Dec 2;119(48):1671-6. doi: 10.1055/s-2008-1058886. Dtsch Med Wochenschr. 1994. PMID: 7988369 Review. German. No abstract available.
Cited by
-
Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses.J Exp Med. 2019 Feb 4;216(2):384-406. doi: 10.1084/jem.20180595. Epub 2019 Jan 23. J Exp Med. 2019. PMID: 30674564 Free PMC article.
-
Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone.J Clin Pharmacol. 2016 Feb;56(2):195-202. doi: 10.1002/jcph.582. Epub 2015 Sep 10. J Clin Pharmacol. 2016. PMID: 26120075 Free PMC article. Clinical Trial.
-
Bioavailability effect of methylprednisolone by polymeric micelles.Pharm Res. 2008 Jan;25(1):39-47. doi: 10.1007/s11095-007-9484-0. Epub 2007 Nov 8. Pharm Res. 2008. PMID: 17990084
-
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. Clin Pharmacokinet. 2005. PMID: 15634032 Review.
-
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.Pharm Res. 1995 Jul;12(7):1096-100. doi: 10.1023/a:1016287104656. Pharm Res. 1995. PMID: 7494809 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources